203 related articles for article (PubMed ID: 17511233)
1. [Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor].
Iwakiri K; Kawami N; Tanaka Y; Sano H; Kotoyori M; Sakamoto C
Nihon Rinsho; 2007 May; 65(5):913-20. PubMed ID: 17511233
[TBL] [Abstract][Full Text] [Related]
2. [Pathogenesis and treatment of refractory gastroesophageal reflux disease in Japanese patients].
Fujiwara Y; Higuchi K; Yamamori K; Watanabe Y; Shiba M; Watanabe T; Tominaga K; Oshitani N; Matsumoto T; Arakawa T
Nihon Rinsho; 2004 Aug; 62(8):1510-5. PubMed ID: 15344542
[TBL] [Abstract][Full Text] [Related]
3. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
[TBL] [Abstract][Full Text] [Related]
4. [PPI: new strategies for GERD].
Hoshino E; Ishiyama A; Tsuchida T
Nihon Rinsho; 2004 Aug; 62(8):1570-6. PubMed ID: 15344553
[TBL] [Abstract][Full Text] [Related]
5. [Test of refractory gastroesophageal reflux disease].
Shimoyama Y; Kuribayashi S; Maeda M; Kusano M
Nihon Rinsho; 2004 Aug; 62(8):1475-82. PubMed ID: 15344537
[TBL] [Abstract][Full Text] [Related]
6. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.
Hillman L; Yadlapati R; Thuluvath AJ; Berendsen MA; Pandolfino JE
Dis Esophagus; 2017 Sep; 30(9):1-15. PubMed ID: 28859358
[TBL] [Abstract][Full Text] [Related]
7. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
Azzam RS
Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
[TBL] [Abstract][Full Text] [Related]
8. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease.
Tack J
Curr Opin Gastroenterol; 2005 Jul; 21(4):454-60. PubMed ID: 15930988
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
Egan LJ; Myhre GM; Mays DC; Dierkhising RA; Kammer PP; Murray JA
Aliment Pharmacol Ther; 2003 Jun; 17(12):1521-8. PubMed ID: 12823155
[TBL] [Abstract][Full Text] [Related]
10. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
11. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.
Iwakiri K; Kinoshita Y; Habu Y; Oshima T; Manabe N; Fujiwara Y; Nagahara A; Kawamura O; Iwakiri R; Ozawa S; Ashida K; Ohara S; Kashiwagi H; Adachi K; Higuchi K; Miwa H; Fujimoto K; Kusano M; Hoshihara Y; Kawano T; Haruma K; Hongo M; Sugano K; Watanabe M; Shimosegawa T
J Gastroenterol; 2016 Aug; 51(8):751-67. PubMed ID: 27325300
[TBL] [Abstract][Full Text] [Related]
12. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.
Koek GH; Sifrim D; Lerut T; Janssens J; Tack J
Gut; 2003 Oct; 52(10):1397-402. PubMed ID: 12970129
[TBL] [Abstract][Full Text] [Related]
13. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
Ichikawa H; Sugimoto M; Sugimoto K; Andoh A; Furuta T
J Gastroenterol Hepatol; 2016 Apr; 31(4):716-26. PubMed ID: 26580676
[TBL] [Abstract][Full Text] [Related]
14. [Underlying Mechanisms and Management of Refractory Gastroesophageal Reflux Disease].
Lee KJ
Korean J Gastroenterol; 2015 Aug; 66(2):70-4. PubMed ID: 26289239
[TBL] [Abstract][Full Text] [Related]
15. Management of Gastroesophageal Reflux Disease.
Gyawali CP; Fass R
Gastroenterology; 2018 Jan; 154(2):302-318. PubMed ID: 28827081
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics of proton pump inhibitors.
Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
[TBL] [Abstract][Full Text] [Related]
17. [Pathogenesis of GERD--peculiarity of NERD].
Kinoshita Y; Furuta K; Adachi K
Nihon Rinsho; 2007 May; 65(5):822-8. PubMed ID: 17511219
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic options for refractory gastroesophageal reflux disease.
Fass R
J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():3-7. PubMed ID: 22486864
[TBL] [Abstract][Full Text] [Related]
19. Step-by-step management of refractory gastresophageal reflux disease.
Hershcovici T; Fass R
Dis Esophagus; 2013 Jan; 26(1):27-36. PubMed ID: 22309405
[TBL] [Abstract][Full Text] [Related]
20. [Pathogenesis of gastro-esophageal reflux disease].
Oshima T; Miwa H
Nihon Rinsho; 2007 May; 65(5):797-801. PubMed ID: 17511216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
